European Society For Medical Oncology

European Commission unveiled the EU Preparedness Union Strategy on 26 March 2025. Central to the initiative is the objective of ‘Protecting Europe's Essential Societal Functions’, which highlights the necessity of ensuring the continuity of critical services, such as healthcare, during crises

New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma

Findings from an exploratory analysis of the ADAURA study

At a time when innovation is more critical than ever in oncology, ESMO is determined to ensure that regulatory developments support, rather than hinder, cancer research in Europe

The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 ESMO Breast Cancer Award is Gabriel N. Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center, USA

Findings from the MonumenTAL-1 study

Findings from the TEMPO study

New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma

Findings from an exploratory analysis of the ADAURA study

Findings from the MonumenTAL-1 study

Findings from the TEMPO study

New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer

Evidence for efficacy is based on the results from the ECHELON-3 study

Biomarker analyses from the CheckMate 649 study

Findings from the MANIFEST-2 study

Findings from the TROPiCS-04 study

The European Lung Cancer Congress 2025 is the event dedicated to the prevention, diagnosis, and management of thoracic malignancies

The ESMO Sarcoma and Rare Cancers Congress 2025, to be held from 20-22 March in Lugano, Switzerland, will be the convergence point for world-renowned experts to present and discuss developments in the diagnosis and treatment of rare solid tumours, going through their peculiar biology and molecular classification, while also addressing the methodological, organisational, and policy challenges that characterise this oncological area and its high unmet needs

Experts predict death rates from all cancers for the EU and UK for 2025

The ESMO Targeted Anticancer Therapies Congress 2025 will showcase state-of-the-art and the latest advancements in new drug development, with focus on new targets, tumour-agnostic drug development, the role of artificial intelligence in drug development, radiotheranostics and cell therapies for solid tumours

The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology

The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region

The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics

Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers

At a time when innovation is more critical than ever in oncology, ESMO is determined to ensure that regulatory developments support, rather than hinder, cancer research in Europe

The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 ESMO Breast Cancer Award is Gabriel N. Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center, USA

The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 Heine H. Hansen Award is Keith Kerr, Consultant Pathologist for NHS Grampian and Honorary Chair in Pulmonary Pathology at the University of Aberdeen in Scotland

Burnout is an increasingly pressing concern for the oncology community

This year marks the 10th anniversary of the ESMO Women for Oncology (W4O) Committee, a decade-long commitment to advancing gender equity in oncology

ESMO reaffirms its commitment to working with EU stakeholders to maximize the potential of the Beating Cancer Plan

Bringing together cancer patient advocates from around the world will create a bridge between diverse experiences and perspectives and help secure the optimisation of patient care worldwide

The nomination process for the 2025 ESMO Society Awards is now open

The European Society for Medical Oncology (ESMO) has announced today that the recipient of the 2025 TAT Honorary Award is Philippe Bedard